ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,214.08
0.51%
US Tech 100
17,690.00
0.28%
다우존스 지수
39,387.76
0.85%
Bitcoin
62,923.05
-0.20%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Janux Therapeutics Inc (JANX)

  7. Janux Therapeutics Inc (JANX) 뉴스

JANX

Janux Therapeutics (JANX)

Janux Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:JANX
일자시간출처헤드라인심볼기업
2024/05/0822:13Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:JANXJanux Therapeutics Inc
2024/05/0805:01Business WireJanux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
2024/03/0906:47Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:JANXJanux Therapeutics Inc
2024/03/0906:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:JANXJanux Therapeutics Inc
2024/03/0906:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2024/03/0906:01Business WireJanux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
2024/03/0107:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
2024/03/0107:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2024/02/2915:22Business WireJanux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:JANXJanux Therapeutics Inc
2024/02/2911:55Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:JANXJanux Therapeutics Inc
2024/02/2907:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2024/02/2811:50Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
2024/02/2807:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2024/02/2807:00Business WireJanux Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:JANXJanux Therapeutics Inc
2024/02/2706:05Business WireJanux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid TumorsNASDAQ:JANXJanux Therapeutics Inc
2024/02/2022:00Business WireJanux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008NASDAQ:JANXJanux Therapeutics Inc
2024/02/1006:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
2024/02/0206:15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
2024/01/0823:00Business WireJanux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific OfficerNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/01/0406:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2023/11/0806:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:JANXJanux Therapeutics Inc
2023/11/0806:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2023/11/0806:01Business WireJanux Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
2023/09/0807:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
2023/08/1505:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
 검색 관련기사 보기:NASDAQ:JANX

최근 히스토리

USOTC
ADDYY
Adidas (QX)
CCOM
US500
US 500
NYSE
NKE
Nike
NYSE
AXP
American Express
PM
XAUUSD
Gold vs US Dollar
USOTC
BASFY
BASF (QX)
NYSE
JPM
JP Morgan Chase
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
US30
US 30
NYSE
CVX
Chevron
CCOM
US100
US Tech 100
USI
USTECH100
US Tech 100
AMEX
XLV
Health Care Select Sector
NASDAQ
NVDA
NVIDIA
CCOM
SILVER
SILVER
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유